Caring Brands, Inc. (NASDAQ:CABR) Shares Shorted: Short Interest Down 55.5% in October

Caring Brands, Inc. (NASDAQ:CABR) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 2,863 shares, a decrease of 55.5% from the September 30th total of 6,427 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 35,362 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Caring Brands in a research report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Caring Brands presently has an average rating of “Sell”.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Susquehanna International Group LLP acquired a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 20,771 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.20% of Caring Brands at the end of the most recent quarter.

Caring Brands Stock Up 5.6%

CABR stock traded up $0.06 during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 101,179 shares, compared to its average volume of 33,897. Caring Brands has a one year low of $0.71 and a one year high of $5.35. The stock has a market capitalization of $11.83 million and a P/E ratio of -1.53. The stock’s 50-day simple moving average is $1.22 and its two-hundred day simple moving average is $1.15.

Caring Brands (NASDAQ:CABR) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.10) earnings per share for the quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.